Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
<h4>Background</h4>There is currently no consensus regarding the optimal number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant chemo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183754&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850079020603932672 |
|---|---|
| author | Young Shin Chung Yun-Ji Kim Inha Lee Jung-Yun Lee Eun Ji Nam Sunghoon Kim Sang Wun Kim Young Tae Kim |
| author_facet | Young Shin Chung Yun-Ji Kim Inha Lee Jung-Yun Lee Eun Ji Nam Sunghoon Kim Sang Wun Kim Young Tae Kim |
| author_sort | Young Shin Chung |
| collection | DOAJ |
| description | <h4>Background</h4>There is currently no consensus regarding the optimal number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant chemotherapy (NAC) and postoperative adjuvant chemotherapy (POAC) cycles on the survival of patients with advanced ovarian cancer undergoing NAC/IDS/POAC.<h4>Methods</h4>We retrospectively reviewed data from 203 patients who underwent NAC/IDS/POAC at Yonsei Cancer Hospital between 2006 and 2016. All patients underwent taxane plus carboplatin chemotherapy for NAC and POAC. The patient outcomes were analyzed according to the number of NAC, POAC, and total chemotherapy (NAC+POAC) cycles.<h4>Results</h4>Patients who received fewer than 6 cycles of total chemotherapy (n = 8) had poorer progression-free survival (PFS) and overall survival (OS) than those completing at least 6 cycles (p = 0.005 and p<0.001, respectively). Among patients who completed at least 6 cycles of total chemotherapy (n = 189), Kaplan-Meier analysis revealed no significant difference in either PFS or OS according to the number of NAC cycles (1-3 vs. ≥4; p = 0.136 and p = 0.267, respectively). Among patients who experienced complete remission after 3 cycles of POAC (n = 98), the addition of further POAC cycles did not improve the PFS or OS (3 vs. ≥4; p = 0.641 and p = 0.104, respectively).<h4>Conclusion</h4>IDS after 4 cycles of NAC may be a safe and effective option when completing 6 cycles of total chemotherapy. Furthermore, the addition of more than 3 cycles of POAC does not appear to influence the survival of patients achieving completion remission after 3 cycles of POAC. |
| format | Article |
| id | doaj-art-df4ced3bfb5447aa8e39228fffcfe6b0 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-df4ced3bfb5447aa8e39228fffcfe6b02025-08-20T02:45:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01129e018375410.1371/journal.pone.0183754Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.Young Shin ChungYun-Ji KimInha LeeJung-Yun LeeEun Ji NamSunghoon KimSang Wun KimYoung Tae Kim<h4>Background</h4>There is currently no consensus regarding the optimal number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant chemotherapy (NAC) and postoperative adjuvant chemotherapy (POAC) cycles on the survival of patients with advanced ovarian cancer undergoing NAC/IDS/POAC.<h4>Methods</h4>We retrospectively reviewed data from 203 patients who underwent NAC/IDS/POAC at Yonsei Cancer Hospital between 2006 and 2016. All patients underwent taxane plus carboplatin chemotherapy for NAC and POAC. The patient outcomes were analyzed according to the number of NAC, POAC, and total chemotherapy (NAC+POAC) cycles.<h4>Results</h4>Patients who received fewer than 6 cycles of total chemotherapy (n = 8) had poorer progression-free survival (PFS) and overall survival (OS) than those completing at least 6 cycles (p = 0.005 and p<0.001, respectively). Among patients who completed at least 6 cycles of total chemotherapy (n = 189), Kaplan-Meier analysis revealed no significant difference in either PFS or OS according to the number of NAC cycles (1-3 vs. ≥4; p = 0.136 and p = 0.267, respectively). Among patients who experienced complete remission after 3 cycles of POAC (n = 98), the addition of further POAC cycles did not improve the PFS or OS (3 vs. ≥4; p = 0.641 and p = 0.104, respectively).<h4>Conclusion</h4>IDS after 4 cycles of NAC may be a safe and effective option when completing 6 cycles of total chemotherapy. Furthermore, the addition of more than 3 cycles of POAC does not appear to influence the survival of patients achieving completion remission after 3 cycles of POAC.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183754&type=printable |
| spellingShingle | Young Shin Chung Yun-Ji Kim Inha Lee Jung-Yun Lee Eun Ji Nam Sunghoon Kim Sang Wun Kim Young Tae Kim Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. PLoS ONE |
| title | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. |
| title_full | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. |
| title_fullStr | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. |
| title_full_unstemmed | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. |
| title_short | Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer. |
| title_sort | impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced stage ovarian cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183754&type=printable |
| work_keys_str_mv | AT youngshinchung impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT yunjikim impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT inhalee impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT jungyunlee impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT eunjinam impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT sunghoonkim impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT sangwunkim impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer AT youngtaekim impactofneoadjuvantchemotherapyandpostoperativeadjuvantchemotherapycyclesonsurvivalofpatientswithadvancedstageovariancancer |